Stroke Treatment Economic Model (STEM)
- 1 December 1999
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 30 (12) , 2574-2579
- https://doi.org/10.1161/01.str.30.12.2574
Abstract
Background and Purpose —Stroke is a debilitating disease with long-term social and economic consequences. As new therapies for acute ischemic stroke are forthcoming, there is an increasing need to understand their long-term economic implications. To address this need, a stroke economic model was created. Methods —The model consists of 3 modules. A short-term module incorporates short-term clinical trial data. A long-term module composed of several Markov submodels predicts patient transitions among various locations over time. The modules are connected via a bridge component that groups the survivors at the end of the short-term module according to their functional status and location. Examples of analyses that can be conducted with this model are provided with the use of data from 2 international trials. For illustration, UK unit costs were estimated. Results —With the trial data in the short-term module, the short-term management cost is estimated to be £8326 (US $13 649 [USD]). Hospital stay was the major cost driver. By the end of the trials, there was a pronounced difference in the distribution of patient locations between functional groups. It is predicted in the long-term module that the subsequent cost amounts to £75 985 (124 564 USD) for a major and £27 995 (45 893 USD) for a minor stroke. Conclusions —Linking functional recovery at the end of short-term treatment with patients’ treatment and residential locations allows this model to estimate the long-term economic impact of stroke interventions. Using patient location instead of the more common natural history as the model foundation allows quantification of the long-term impact to become data driven and hence increases confidence in the results.Keywords
This publication has 16 references indexed in Scilit:
- Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic StrokeCerebrovascular Diseases, 1998
- Longer term quality of life and outcome in stroke patients: is the Barthel index alone an adequate measure of outcome?Quality and Safety in Health Care, 1997
- The Use of Consensus Methods and Expert Panels in Pharmacoeconomic StudiesPharmacoEconomics, 1997
- The Burden of Stroke and its SequelaeDisease Management and Health Outcomes, 1997
- Predicting discharge destination of stroke patients using a mathematical model based on six items from the functional independence measureArchives of Physical Medicine and Rehabilitation, 1996
- C5. Beyond acute care: the true cost of strokeClinical Therapeutics, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Can we learn lessons from the different ways stroke is managed in different countries?Journal of the Royal Society of Health, 1995
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- Direct Costs of Stroke for a Swedish PopulationInternational Journal of Technology Assessment in Health Care, 1990